SYNTHESIS OF BICYCLIC DERIVATIVES OF 5A-CARBA-SUGARS: 6-HYDROXYL GROUP CONFORMATIONALLY RESTRICTED 5A-CARBA-D-MANNOPYRANOSE DERIVATIVES


Seiichiro Ogawa,* Masatsugu Ohno, and Takashi Ohhira


Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Hiyoshi, Kohoku-ku, Yokohama, 223-8522 Japan


<u>Abstract</u>— Some bicyclic derivatives of 5a-carba- α - and β -D-mannopyranoses, whose 6-hydroxyl groups are conformationally restricted, have been synthesized in order to provide key components of the trisaccharide mimics designed as inhibitors or substrate analogues useful for elucidation of mechanism and action of GlcNAcT-V.


INTRODUCTION


N-Acetylglucosaminyltransferase (GlcNAcT-V) is a key enzyme involved in the biosynthesis of highly branched asparagine-linked oligosaccharides.¹ This enzyme has been focused much attention since, especially, specific increases in the activity of this enzyme have been shown to correlate with the metastatic potential of human and rodent tumor cells.^{2,3} Hindsgaul and his coworkers⁴ have found that simple synthetic trisaccharide (1) is a substrate acceptor for GlcNAcT-V yielding the expected tetrasaccharide (3) (Scheme 1). Extensive chemical modification⁵ of 1 has so far been carried out both to elucidate mechanism and action of this enzyme, and to develop possible inhibitors of this enzyme. On the other hand, the enzyme has been shown to recognize this acceptor (1) in only one of these two accessible conformations (gauche-trans or gauche-gauche rotamer), derived by restriction of rotation about the α -D-Man*p*-(1→6) linkage, on the basis of the study⁶ using the substrate analogues, the conformations of which were fixed by linking O4 and C6 with an ethylene bridge. We have previously shown⁷ that the trisaccharide mimic (2), the central α -D-mannopyranose unit of 1 being replaced with the 5a-carba congener, acts similarly as the effective acceptor for GlcNAcT-V to
















Scheme 1







Scheme 3

afford the tetrasaccharide (4). Therefore, the 6-OH group conformationally restricted derivatives (9α) and (10α) (gg and gt rotamers) of 5a-carba-D-mannopyranose, 2-oxabicyclo[4.4.0]decane-5,7,8,9,10pentols, were designed and synthesized, in order to demonstrate whether both the target 5a-carbatrisaccharides (5) and (6) of gg and gt conformers act as a substrate for GlcNAcT-V or not. Besides 9β and 10β may be useful building blocks for preparation of the carba-trisaccharides such as 7 and 8, in which the possibility for rotation about C-5-C-6 bond of α -D-Man residue are restricted. Compounds (9α , β) and (10α , β) itself may be applied as D-mannopyranose mimics for certain biochemical studies.

RESULTS AND DISCUSSION

The epoxide⁸(11), a versatile intermediate for synthesis of 5a-carba-oligosaccharides, was easily available from optically resolved Diels-Alder endo-adduct of furan and acrylic acid. Treatment of 11 with LiBr and NiBr in THF, followed by acetylation, gave the bromide (12) (~100%) (Scheme 2). On treatment with DBU in toluene at 70°C, elimination reaction of 12 underwent smoothly to give the alkene (13) (88%), which was converted into the dibenzyl ether (14) (87%) by Zemplén O-deacetylation and subsequent O-benzylation. Treatment of 14 with OsO_4 in the presence of N-methylmorpholine in aqueous acetone afforded selectively a single diol, which was isolated as the diacetate⁹ (15) ($\sim 100\%$). The structure was assigned on the basis of the ¹H NMR spectrum. The protecting O-acetyl groups of 15 were replaced with p-methoxybenzyl (MPM), by O-deacetylation and subsequent treatment with NaH and *p*-methoxybenzyl chloride in DMF (\rightarrow 16, 90%), being more suitable for the proceeding steps. Compound 16 was then O-debenzylidenated with aqueous 80% AcOH. Selective benzoylation of the resulting diol with BzCl in pyridine $(-15^{\circ}C)$ gave the 6-benzoate (17) (87% over-all yield). A solution of 17 in dry DMF was first treated with slightly excess of NaH (~ 2 molar equiv.) and then with excess benzyl bromide to produce three monobenzyl ethers (18) (58%), (19) (26%), and (20) (11%). Compound (18) was readily convertible to the desired 19 by treatment with DIBAH in toluene in 97% yield. Oxidation of 19 with DMSO-oxalyl chloride in CH_2Cl_2 gave the aldehyde (21), which was subsequently treated with ethenylmagnesium bromide in THF at -78 °C to give a mixture of the isomeric alcohols (22) (80% over-all yield). The mixture was without separation converted into the methoxymethyl ethers (23) (92%), which were hydroborated (->24, 86%) and then transformed conventionally into the tosylates $(\rightarrow 25, 85\%)$. The MPM groups were removed with CAN in aqueous CH₃CN and the resulting diols were subjected to basic conditions with methanolic sodium methoxide to give rise to a mixture of

products, which was separated by chromaqtography on silica gel to give two bicyclic compounds¹⁰ (26) (39%) and (28) (33%). They were further characterized as the acetates (27) (73%) and (29) (70%), whose structures were fully assigned on the basis of their ¹H NMR spectra. These are the appropriately protected derivatives of 9α and 10α , utilizable for further transformation. Inversion of the configuration at C-10, corresponding to the anomeric position of 5a-carba-D-manno-pyranose derivatives, was carried out by oxidation of the 10-OH group and subsequent reduction (Scheme 3). Thus, treatment of 26 with acetic anhydride in DMSO gave the ketone (30) (~100%), which was reduced with L-selectride in THF to afford the β -anomer¹¹ (31) (74%). Removal of the methoxymethyl group with hydrochloric acid in H₂O-THF and successive hydrogenolysis in the presence of 10% Pd/C gave the free carba-sugar derivative (9β) (95%), [α]_D²¹ +9.2° (c 0.5, MeOH). Similarly, compound (28) was transformed into 10 β (40% over-all yield), [α]_D²⁴ +49° (c 0.3, MeOH), through 32 and 33¹²

ACKNOWLEDGMENT

We sincere thank Mr. K. Hokazono for performing elemental analyses and Prof. O. Hindsgaul (University of Alberta, Canada) for suggestions for design of the compounds.

REFERENCES AND NOTES

- 1. R. D. Cummings, I. S. Trowbridge, and S. Kornfeld, J. Biol. Chem., 1982, 257, 13421.
- 2. H. Schachter, Biochem. Cell. Biol., 1986, 64, 163.
- J. W. Dennis, S. Laferte, C. Waghorne, M. L. Breitman, and R. S. Kerbel, *Science*, 1987, 236, 582;
 J. W. Dennis, *Cancer Surveys*, 1988, 7, 573.
- 4. O. Hindsgaul, S. H. Tahir, O. P. Srivastava, and M. Pierce, Carbohydr. Res., 1988, 173, 263.
- O. Hindsgaul, I. Lindh, N. J. Dovichi, J. Y. Zhao, S. C. Crawley, S. Gosselin, and M. M. Palcic, 'Complex Carbohydrates in Drug Research (Alfred Benzon Symposium 36)', ed. by K. Bock, H. Kaulsen, P. Krogsgaard-Larsen, and H. Kofod, Munksgaard International Publishers, Copenhagen, 1994, pp. 104-117.
- 6. I. Lindh and O. Hindsgaul, J. Am. Chem. Soc., 1991, 113, 216.
- S. Ogawa, T. Furuya, H. Tsunoda, O. Hindsgaul, K. Stangier, and M. M. Palcic, Carbohydr. Res., 1995, 271, 197.
- 8. S. Ogawa, S. Sasaki, and H. Tsunoda, Carbohydr. Res., 1995, 274, 183.
- 9. Compound (15): $[\alpha]_D^{23} 11^\circ$ (c 2.6, CHCl₃); ¹H NMR (270 MHz, CDCl₃): $\delta = 7.54 7.30$ (m, 15 H, 3 × Ph), 5.63 (s, 1 H, 3-H), 5.41 (dd, $J_{7,8} = 2.9, J_{8,9} = 3.7$ Hz, 1 H, 8-H), 5.09 (dd, $J_{6,7} = 11.9, J_{7,8} = 2.9$ Hz, 1 H, 7-H), 4.82 (d, $J_{gen} = 12.1$ Hz, 1 H, PhCH₂), 4.76 (s, 2 H, PhCH₂), 4.61 (d, $J_{gen} = 12.1$

61

Hz, 1 H, PhCH₂), 4.25 (dd, $J_{1,6} = 11.0$, $J_{1,10} = 9.2$ Hz, 1 H, 1-H), 4.18 (dd, $J_{gern} = 11.0$, $J_{5eq,6} = 4.2$ Hz, 1 H, 5eq-H), 3.82 (dd, $J_{1,10} = 9.2$, $J_{9,10} = 2.9$ Hz, 1 H, 10-H), 3.80 (dd, $J_{8,9} = 3.7$, $J_{9,10} = 2.9$ Hz, 1 H, 9-H), 3.76 (dd, $J_{gern} = J_{5ax,6} = 11.0$ Hz, 1 H, 5ax-H), 2.43 (dddd, $J_{1,6} = J_{5ax,6} = 11.0$, $J_{5eq,6} = 4.2$, $J_{6,7} = 11.9$ Hz, 1 H, 6-H), 2.03 and 2.02 (2 s, each 3 H, 2 × Me).

- Compound (26): $[\alpha]_D^{23} + 26^\circ$ (c 0.4, CHCl₃); ¹H NMR (270 MHz, CDCl₃): $\delta = 7.35 7.22$ (m, 15 H, 10. $3 \times Ph$), 4.88 (d, $J_{gem} = 11.0$ Hz, 1 H, PhCH₂), 4.78 (d, $J_{gem} = 12.1$ Hz, 1 H, PhCH₂), 4.67–4.53 (m, 6 H, MeOCH₂, 2 × PhCH₂), 4.07 (dd, $J_{1.10}$ = 3.1, $J_{9.10}$ = 2.8 Hz, 1 H, 10-H), 4.01 (ddd, J_{eem} = 11.8, $J_{3eq.4ax} = 5.1$, $J_{3eq.4ex} = 1.5$ Hz, 1 H, 3eq-H), 3.95 (dd, $J_{7.8} = 8.8$, $J_{8.9} = 2.7$ Hz, 1 H, 8-H), 3.93 (dd, $J_{8,9} = J_{9,10} = 2.7$ Hz, 1 H, 9-H), 3.81 (dd, $J_{6,7} = 9.5$, $J_{7,8} = 8.8$ Hz, 1 H, 7-H), 3.71 (ddd, $J_{4ax,5} = 10.6$, $J_{4eq.5} = 4.8, J_{5.6} = 10.1$ Hz, 1 H, 5-H), 3.54 (ddd, $J_{gem} = J_{3ax,4ax} = 11.8, J_{3ax,4eq} = 2.6$ Hz, 1 H, 3ax-H), $3.44 \text{ (dd, } J_{1.6} = 10.3, J_{1.10} = 3.1 \text{ Hz}, 1 \text{ H}, 1 \text{ -H}), 3.30 \text{ (s, 3 H, Me)}, 2.13 \text{ (ddd, } J_{1.6} = 10.3, J_{5.6} = 10.1,$ $J_{6,7} = 9.5$ Hz, 1 H, 6-H), 2.10 (dddd, $J_{gem} = 12.8$, $J_{3ax,4eq} = 2.5$, $J_{3eq,4eq} = 1.5$, $J_{4eq,5} = 4.8$ Hz, 1 H, 4eq-H), 1.72 (dddd, $J_{gen} = 12.8$, $J_{3ax,4ax} = 11.8$, $J_{3eq,4ax} = 5.1$, $J_{4ax,5} = 10.6$ Hz, 1 H, 4ax-H). Compound (28): $[\alpha]_D^{23}$ +2.3° (c 1.5, CHCl₃); ¹H NMR (270 MHz, CDCl₃): δ = 7.40–7.26 (m, 15 H, $3 \times Ph$), 5.05 (d, $J_{eem} = 11.0$ Hz, 1 H, PhCH₂), 4.79 (d, $J_{eem} = 12.1$ Hz, 1 H, PhCH₂), 4.71–4.63 (m, 5 H, RC H_2), 4.56 (d, $J_{\text{eern}} = 11.0$ Hz, 1 H, RC H_2), 4.25 (ddd, $J_{4\text{ax},5} = 2.2$, $J_{4\text{eer},5} = J_{5,6} = 2.6$ Hz, 1 H, 5-H), 4.07 (ddd, J_{1,10} = J_{9,10} = 3.1, J_{10,0H} = 1.1 Hz, 1 H, 10-H), 3.98–3.88 (m, 5 H, 1-H, 3ax-H, 7-H, 8-H, 9-H), 3.82 (br dd, $J_{gen} = 11.1$, $J_{3eq,4ax} = 4.8$ Hz, 1 H, 3eq-H), 3.37 (s, 3 H, Me), 1.96–1.86 (m, 2 H, 4eq-H, 6-H), 1.67 (dddd, $J_{gem} = 13.3$, $J_{3ax,4ax} = 12.5$, $J_{3eq,4ax} = 5.1$, $J_{4ax,5} = 2.2$ Hz, 1 H, 4ax-H).
- 11. Compound (**31**): $[\alpha]_D^{23}$ -4.1° (c 1.3, CHCl₃); ¹H NMR (270 MHz, CDCl₃): $\delta = 7.41-7.20$ (m, 15 H, 3 × Ph), 4.96 (d, $J_{gem} = 11.7$ Hz, 1 H, PhC H_2), 4.89 (d, $J_{gem} = 10.6$ Hz, 1 H, PhC H_2), 4.77 (d, $J_{gem} = 11.4$ Hz, 1 H, PhC H_2), 4.66-4.55 (m, 5 H, RC H_2), 4.08 (dd, $J_{8,9} = 2.4$, $J_{9,10} = 2.7$ Hz, 1 H, 9-H), 4.03 (ddd, $J_{gem} = 11.8$, $J_{3eq,4ax} = 5.2$, $J_{3eq,4eq} = 1.3$ Hz, 1 H, 3eq-H), 3.87 (dd, $J_{6,7} = 9.9$, $J_{7,8} = 9.5$ Hz, 1 H, 7-H), 3.70 (ddd, $J_{4ax,5} = 10.6$, $J_{4eq,5} = 4.4$, $J_{5,6} = 10.2$ Hz, 1 H, 5-H), 3.57 (dd, $J_{1,10} = 9.9$, $J_{9,10} = 2.7$ Hz, 1 H, 10-H), 3.54 (dd, $J_{7,8} = 9.5$, $J_{8,9} = 2.4$ Hz, 1 H, 8-H), 3.48 (ddd, $J_{gem} = J_{3ax,4ax} = 11.8$, $J_{3ax,4eq} = 1.4$ Hz, 1 H, 3ax-H), 3.34 (dd, $J_{1,6} = 10.3$, $J_{1,10} = 9.9$ Hz, 1 H, 1-H), 3.30 (s, 3 H, Me), 2.13 (dddd, $J_{gem} = 12.9$, $J_{3ax,4eq} = J_{3cq,4eq} = 1.3$, $J_{4eq,5} = 4.4$ Hz, 1 H, 4eq-H), 1.76 (dddd, $J_{gem} = 12.9$, $J_{3ax,4ax} = 11.8$, $J_{3eq,4ax} = 5.2$, $J_{4ax,5} = 10.6$ Hz, 1 H, 4ax-H), 1.67 (ddd, $J_{1,6} = 10.3$, $J_{5,6} = 10.2$, $J_{6,7} = 9.9$ Hz, 1 H, 6-H).
- 12. Compound (33): $[\alpha]_D^{24} + 2.5^{\circ}$ (c 0.9, CHCl₃); ¹H NMR (270 MHz, CDCl₃): $\delta = 7.43-7.25$ (m, 15 H, 3 × Ph), 5.04 (d, $J_{gem} = 12.1$ Hz, 1 H, PhC H_2), 5.04 (d, $J_{gem} = 11.0$ Hz, 1 H, PhC H_2), 4.76 (d, $J_{gem} = 12.1$ Hz, 1 H, PhC H_2), 4.72–4.61 (m, 4 H, 2 × RC H_2), 4.58 (d, $J_{gem} = 11.0$ Hz, 1 H, RC H_2), 4.76 (d, $J_{gem} = 12.1$ Hz, 1 H, PhC H_2), 4.72–4.61 (m, 4 H, 2 × RC H_2), 4.58 (d, $J_{gem} = 11.0$ Hz, 1 H, RC H_2), 4.18 (ddd, $J_{4ax,5} = J_{4cq,5} = 2.6$, $J_{5,6} = 2.4$ Hz, 1 H, 5-H), 4.09 (dd, $J_{8,9} = 2.6$, $J_{9,10} = 2.7$ Hz, 1 H, 9-H), 4.00 (dd, $J_{6,7} = 10.7$, $J_{7,8} = 9.5$ Hz, 1 H, 7-H), 3.96–3.80 (m, 2 H, 3-H₂), 3.81 (dd, $J_{1,6} = 10.7$, $J_{1,10} = 9.5$ Hz, 1 H, 1-H), 3.52 (dd, $J_{7,8} = 9.5$, $J_{8,9} = 2.6$ Hz, 1 H, 8-H), 3.46 (dd, $J_{1,10} = 9.5$, $J_{9,10} = 2.7$ Hz, 1 H, 10-H), 3.37 (s, 3 H, Me), 1.93 (dddd, $J_{gem} = 13.6$, $J_{3ax,4eq} = J_{3eq,4eq} = 1.5$, $J_{4eq,5} = 2.6$ Hz, 1 H, 4eq-H), 1.69 (dddd, $J_{gem} = 13.6$, $J_{3ax,4ax} = 11.4$, $J_{3eq,4ax} = 7.0$, $J_{4ax,5} = 10.7$, $J_{5,6} = 2.4$ Hz, 1 H, 4ax-H), 1.42(ddd, $J_{1,6} = J_{6,7} = 10.7$, $J_{5,6} = 2.4$ Hz, 1 H, 6-H).

Received, 29th June, 1998